Cargando…
Combination strategies to maximize the benefits of cancer immunotherapy
Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy (ACT) have revolutionized cancer treatment, especially in patients whose disease was otherwise considered incurable. However, primary and secondary resistance to single agent immunotherapy often results in treatment f...
Autores principales: | Zhu, Shaoming, Zhang, Tian, Zheng, Lei, Liu, Hongtao, Song, Wenru, Liu, Delong, Li, Zihai, Pan, Chong-xian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475356/ https://www.ncbi.nlm.nih.gov/pubmed/34579759 http://dx.doi.org/10.1186/s13045-021-01164-5 |
Ejemplares similares
-
Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy
por: Pan, Chongxian, et al.
Publicado: (2020) -
Novel strategies for immuno-oncology breakthroughs with cell therapy
por: Liu, Hongtao, et al.
Publicado: (2021) -
Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing
por: Li, Zihai, et al.
Publicado: (2018) -
The role of biomarkers in personalized immunotherapy
por: Sankar, Kamya, et al.
Publicado: (2022) -
PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
por: Wang, Jun, et al.
Publicado: (2017)